Having recently written about the significant headwinds pushing against Amedisys (NASDAQ:AMED), I now turn to its smaller but more profitable rival LHC Group (NASDAQ:LHCG). Like Amedisys, LHC Group is looking at an operating environment dominated by further cuts in Medicare reimbursement. Unlike Amedisys, though, I believe LHC Group may be able to leverage its strong network of hospital joint ventures and benefit from its exposure to rural locations and growing hospice revenue to offset this pressure.
Make no mistake, the next few years will not be easy ones for LHC Group. Although I believe that LHCG is likely to do better than most in terms of admissions and margins, the next couple of years could be...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|